This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 55.77% and 347.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Top Stocks to Play Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD).
Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
by Zacks Equity Research
Atyr Pharma (LIFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
5 Top Stocks Likely to Top Earnings Estimates
by Sanghamitra Saha
Top-ranked stocks Yum China (YUMC), Amazon.com (AMZN), Workday (WDAY), aTyr Pharma (LIFE) and D.R. Horton (DHI) are likely to beat on the bottom line in their upcoming releases.
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 18.52% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 25.64% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -29.41% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod
by Zacks Equity Research
The FDA bestows an Orphan Drug status to aTyr Pharma's (LIFE) lead candidate, efzofitimod, for the treatment of systemic sclerosis. Shares rise.
Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 235.8% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Atyr Pharma (LIFE) Climb 266% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 265.6% upside potential for Atyr Pharma (LIFE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 5.41% and 4.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Atyr Pharma (LIFE) Could Rally 112%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Atyr Pharma (LIFE) points to an 111.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Atyr Pharma (LIFE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 20.75% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About aTyr Pharma (LIFE) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.
aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923
by Zacks Equity Research
aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.
Are Options Traders Betting on a Big Move in aTyr Pharma (LIFE) Stock?
by Zacks Equity Research
Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.
Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -39.13% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Atyr Pharma (LIFE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -50.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Atyr Pharma (LIFE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.